Antithrombogenicity of a centrifugal pump (CP) developed in our instit
ute is provided by a central balancing hole (BH) in the impeller. A cu
rrent CP, the National Cardiovascular Center (NCVC)-2, was ameliorated
to improve antithrombogenicity, whereby the BH diameter was widened t
o improve self washout flow velocity, and an edge of the thrust bearin
g was rounded off to minimize flow separation. Effects of these modifi
cations were assessed in a long-term in vivo experiment. The antithrom
bogenicity, hemolytic property, and mechanical durability of the NCVC-
2 were investigated in 3 goats. The NCVC-2 was installed paracorporeal
ly between the left atrium and the aorta and driven as long as possibl
e at rotating speeds of about 2,800 rpm. The NCVC-2 ran for 50, 200, a
nd 367+ days. The mean bypass flow rates were 6.8, 5.0, and 5.3 L/min,
respectively. Creatinine, blood urea nitrogen (BUN), glutamic-oxaloac
etic transaminase (GOT), and glutamic-pyruvic transaminase (GPT) did n
ot increase until one week before termination. Plasma free hemoglobin
was kept to a level less than 15 mg/dl, except for the last week of th
e second case. These results indicate that the NCVC-2 has excellent an
tithrombogenicity, an acceptable hemolytic property and the necessary
durability for prolonged use.